On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) jointly announced the RAPID Coverage Pathway (“Regulatory Alignment for Predictable and Immediate Device” coverage), a new mechanism intended to close the long gap between FDA market authorization of a breakthrough medical device and the point at which Medicare actually pays for it. Under the prior status quo, that gap routinely ran a year or more; CMS says RAPID is designed to bring it down to roughly 60-90 days for eligible devices. This post walks through what was announced, how RAPID is meant to work, how it relates to the coverage mechanisms CASRAI already covers in depth (NCD 310.1, TCET, and Coverage with Evidence Development), and where the rulemaking stands as of mid-2026.
What was announced
CMS and FDA released companion press statements on April 23, 2026 describing RAPID as a jointly designed process for aligning the two agencies’ evidence expectations earlier in a device’s development, so that the clinical evidence generated to support FDA market authorization can also support a Medicare national coverage determination (NCD) without a second, sequential evidence-gathering cycle. Multiple law-firm client alerts published the same week (Foley Hoag, Orrick, Latham & Watkins) and trade-press coverage (STAT News, Healthcare Dive, MedTech Dive) corroborate the date and the core mechanics; this page treats those as consistent, independently reported accounts of a single joint federal announcement, not a single unverified source.
The headline mechanism: CMS can issue a proposed NCD the same day as FDA market authorization for an eligible device, rather than waiting for a manufacturer to separately request coverage after authorization. That proposed NCD then follows the standard 30-day public comment process contemplated for NCDs, rather than the open-ended, often multi-year timeline that has applied when CMS starts its own coverage analysis from scratch post-authorization.
Who is eligible
RAPID is scoped narrowly, not to every FDA-authorized device. Based on the joint announcement and the law-firm alerts summarizing it, eligibility requires:
- FDA Breakthrough Device designation (the existing FDA program for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions) — RAPID layers onto Breakthrough Device status, it does not create a new device-designation category itself.
- For Class II devices: participation in FDA’s Total Product Life Cycle Advisory Program (TAP).
- For Class III devices: eligible regardless of TAP participation.
- The device must be the subject of an active Investigational Device Exemption (IDE) study that enrolls Medicare beneficiaries and is built around clinical outcomes CMS and FDA have agreed on in advance.
CMS officials cited publicly at the time of announcement estimated roughly 40 currently-authorized or in-development devices would qualify outright, with another 20 or so potentially eligible depending on how their trials are structured going forward.
Where this sits relative to TCET and CED
RAPID is not the first attempt CMS has made at compressing this timeline. TCET (Transitional Coverage for Emerging Technologies), finalized in August 2024, offered Breakthrough Devices an expedited coverage review process built around a CMS-led evidence-development plan. As part of the RAPID announcement, CMS said it is pausing TCET for new candidate devices while it stands up RAPID — existing TCET participants are not described as being displaced, but the pathway is not accepting new entrants going forward.
Coverage with Evidence Development (CED) is a separate, older CMS mechanism that conditions coverage of an item or service on continued data collection through a registry or trial (used historically for things like CAR-T therapies and TAVR). CED is not being retired by RAPID and remains a distinct tool CMS can still apply, including potentially alongside a RAPID-track NCD for a given device.
None of RAPID, TCET, or CED changes the separate NCD 310.1 “qualifying clinical trial” routine-costs policy, which governs whether Medicare covers routine patient-care costs during a qualifying drug or biologic trial under an IND. RAPID and TCET instead sit on the device-specific track already documented in CASRAI’s coverage of Category A vs. Category B IDE studies, which explains how Medicare decides whether to pay for the investigational device itself (as opposed to routine care) during an IDE study. RAPID is best understood as a faster on-ramp to a national coverage determination for a narrow slice of high-priority Breakthrough Devices, not a replacement for that underlying IDE-category framework.
Why the acceleration matters
Before RAPID, the standard sequence for a newly FDA-authorized breakthrough device was: FDA market authorization, then — separately — a manufacturer request for Medicare coverage, then CMS’s own coverage analysis (which could include opening a new NCD, relying on existing Local Coverage Determinations that vary by Medicare Administrative Contractor, or defaulting to case-by-case claim review). CMS and FDA both described that sequential process as routinely taking a year or longer end to end, during which a device with FDA market authorization frequently has no defined Medicare payment path at all, even though a large share of the patients most likely to need it are Medicare beneficiaries by definition of the conditions Breakthrough Devices tend to target (e.g., late-stage disease, rare and severe pediatric-to-adult conditions, age-associated conditions).
CMS’s stated target under RAPID — national coverage finalized roughly 60-90 days after FDA market authorization — compresses that gap by aligning the evidence-generation work itself, not just the paperwork after the fact: the IDE study underpinning FDA authorization is, for RAPID-eligible devices, built from the outset around endpoints both agencies have pre-agreed will also support the coverage decision.
Regulatory process and current status
RAPID does not take effect through the joint press announcement alone. CMS’s own description of the process calls for a proposed procedural notice in the Federal Register, followed by a 60-day public comment period, before a final notice establishes the pathway’s operational effective date. Based on the April 23, 2026 announcement date, that 60-day comment window would have closed in the June 2026 timeframe; as of this writing, CMS has not yet published the final notice. Research administrators and coverage-analysis staff tracking RAPID-eligible devices should watch for that final Federal Register notice rather than treating the pathway as fully operational based on the April announcement alone — the announcement describes CMS and FDA’s intent and the proposed mechanics, not a pathway that is yet finalized and accepting devices end-to-end.
A related, separate CMS proposal reported by law firms in May 2026 would also revisit the New Technology Add-on Payment (NTAP) “alternative pathway” for breakthrough devices alongside RAPID’s rollout. That NTAP proposal is a distinct payment-methodology question (how much Medicare pays per case under the inpatient prospective payment system) rather than a coverage-determination question (whether Medicare pays at all) — worth tracking separately, but not part of the RAPID coverage mechanism itself.
What this means for research administrators and coverage-analysis teams
For institutions running device trials under an IDE, RAPID raises the practical stakes of two things CASRAI already covers in depth: getting the investigational device‘s Category A/B classification right early (RAPID eligibility depends on Breakthrough Device status and TAP/Class distinctions layered on top of that), and building Medicare-beneficiary enrollment and outcome-tracking into the IDE protocol from the start, since RAPID explicitly requires the underlying IDE study to enroll Medicare beneficiaries against pre-agreed clinical outcomes. Coverage-analysis and billing-compliance staff should also not assume RAPID is live for a given device simply because it holds Breakthrough Device designation — confirm against the final Federal Register notice once published, and continue applying the existing NCD/LCD framework and Medicare coverage-analysis process in the interim.
Sources
- CMS, “CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices,” press release, April 23, 2026 (cms.gov/newsroom).
- FDA, companion press announcement, April 23, 2026 (fda.gov/news-events/press-announcements).
- Foley Hoag LLP, “CMS and FDA Announce RAPID Coverage Pathway to Accelerate Medicare Coverage for Breakthrough Medical Devices,” client alert, April 2026.
- Orrick, “RAPID Response: CMS and FDA Team Up to Fast-Track Medicare Coverage for Breakthrough Devices,” April 2026.
- Latham & Watkins, “CMS and FDA Announce New RAPID Program for Medicare Coverage of Breakthrough Medical Devices,” April 2026.
- STAT News and Healthcare Dive, contemporaneous news coverage, April 23, 2026.
- Ropes & Gray LLP, coverage of the related proposed NTAP “alternative pathway” repeal, May 2026.
